Employers are Scaling AI Use in Health Benefits, but Face Challenges
A new WTW survey found that employers are rapidly adopting AI in health benefits despite…
Employers are Scaling AI Use in Health Benefits, but Face Challenges
A new WTW survey found that employers are rapidly adopting AI in health benefits despite concerns about governance, resources, privacy and compliance. The post Employers are Scaling AI Use in Health Benefits, but Face Challenges appeared first on MedCity News.
Eli Lilly’s Vaccine Acquisitions Signal a Strategy of Growth in New Areas
Eli Lilly is spending up to $3.8 billion to buy vaccines in development for shingles, staph infections, and Epstein-Barr virus as well as the platform technologies that spawned these programs. The pharmaceutical giant indicated interest in infectious disease last year when it hired Peter Marks, former director of the FDA division that oversees vaccines. The…
Health Systems Can’t Ignore Legacy Cybersecurity Risks
Unsupported legacy applications are no longer just technical debt. Once you know they have control gaps, they become a source of security, compliance, legal and financial exposure.
Digital Health Keeps Measuring Engagement While Ignoring Tolerability
Engagement still matters. But the more important question is whether the intervention respects the human nervous system of the person on the receiving end. The post Digital Health Keeps Measuring Engagement While Ignoring Tolerability appeared first on MedCity News.
AI Health Check: No Governance, No Trust
Will doctors or patients who are burned by one AI solution trust the next one they’re given? Probably not. That’s why every provider rolling out AI tools has to understand this risk and build governance into its development process. The post AI Health Check: No Governance, No Trust appeared first on MedCity News.
The Silent Threat — Why Early Lymphedema Detection Matters for Breast Cancer Survivors
As breast cancer treatment continues to improve, our focus must expand beyond survival to encompass the quality of life during and after treatment. The post The Silent Threat — Why Early Lymphedema Detection Matters for Breast Cancer Survivors appeared first on MedCity News.
Cheaper, Alternative Health Plans Are Having a Moment, but Critics Urge Caution
When Melanie Miller saw that her health insurance premium payment was set to nearly triple to $914 a month this year, she stopped shopping on the Affordable Care Act marketplace. The 59-year-old retired teacher, who recently moved from Ohio to Michigan, now pays $341 a month for a pair of plans, one that covers routine…
AI at Scale: Does It Deliver?
How is AI applied to clinical care and hospital operations across a real health system at full scale? Chip Kahn talks to Dr. Michael Schlosser, Senior Vice President and Chief Transformation Officer at HCA Healthcare, about how AI is developed for everyday use, starting with careful testing and customization, with clinicians and nurses engaged from…
AstraZeneca, Daiichi Drug Approved as New First-Line Therapy for Tough Type of Breast Cancer
Datroway landed its third FDA approval in the past 18 months, this time as a treatment for triple negative breast cancer. The antibody drug conjugate was developed under a broad collaboration between Daiichi Sankyo and AstraZeneca. The post AstraZeneca, Daiichi Drug Approved as New First-Line Therapy for Tough Type of Breast Cancer appeared first on…
Precision Medicine’s Next Hurdle Isn’t Science — It’s Execution
A new UPMC report found that while most health systems now offer precision medicine programs, many still face challenges scaling them due to reimbursement, data integration and patient engagement issues. Health system leaders say the field’s future depends on embedding genomics into routine care, as well as proving its clinical and financial value. The post…
